

ER+/ HER2 -ve Breast Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/EE3BCD247134EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: EE3BCD247134EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "ER+/ HER2 -ve Breast Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ER+/ HER2 -ve Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

ER+/ HER2 -ve Breast Cancer Understanding

ER+/ HER2 -ve Breast Cancer: Overview

Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. Most breast cancers express the estrogen receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. The backbone of their systemic therapy consists of hormonal therapies that block the function of ER through various mechanisms. These include blockade of the receptor itself in breast cancer cells, blockade of the production of its major ligand, estradiol, or degradation of the receptor. However, a subset of ER+/HER2? breast cancers, mostly corresponding to the genomic luminal B genotype, are resistant to hormonal manipulations from the outset of therapies.

“ER+/ HER2 -ve Breast Cancer- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ER+/ HER2 -ve Breast Cancer pipeline landscape is provided which includes the disease overview and ER+/ HER2 -ve Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth ER+/ HER2 -ve Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ER+/ HER2 -ve Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence ER+/ HER2 -ve Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve ER+/ HER2 -ve Breast Cancer.

ER+/ HER2 -ve Breast Cancer Emerging Drugs Chapters

This segment of the ER+/ HER2 -ve Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

ER+/ HER2 -ve Breast Cancer Emerging Drugs

H3B-6545: Eisai

An orally administered selective estrogen receptor alpha (ER?) covalent antagonist that inhibits ER? wild type / ER? mutant. Expected to show an antitumor effect against ER positive / HER2 negative breast cancers.

Rintodestrant (G1T48): G1 Therapeutics

Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader

(SERD) in development for the treatment of ER+ breast cancer. Preclinical data have shown rintodestrant to be more potent than fulvestrant, currently the only FDA-approved SERD. The company initiated a phase 1/2a trial of rintodestrant in ER+/HER2 -ve breast cancer.

GDC-9545: Genetech/ La Roche

GDC-9545 is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.

Further product details are provided in the report.....

ER+/ HER2 -ve Breast Cancer: Therapeutic Assessment

This segment of the report provides insights about the different ER+/ HER2 -ve Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in ER+/ HER2 -ve Breast Cancer

There are approx. 5+ key companies which are developing the therapies for ER+/ HER2 -ve Breast Cancer. The companies which have their ER+/ HER2 -ve Breast Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Eisai and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

ER+/ HER2 -ve Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Parenteral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Peptides

Polymer

Gene Therapy

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

ER+/ HER2 -ve Breast Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ER+/ HER2 -ve Breast Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ER+/ HER2 -ve Breast Cancer drugs.

ER+/ HER2 -ve Breast Cancer Report Insights

ER+/ HER2 -ve Breast Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

ER+/ HER2 -ve Breast Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing ER+/ HER2 -ve Breast Cancer drugs?

How many ER+/ HER2 -ve Breast Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ER+/ HER2 -ve Breast Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ER+/ HER2 -ve Breast Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for ER+/ HER2 -ve Breast Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Eisai

G1 Therapeutics

Genetech/La Roche

Sanofi

AstraZeneca

Key Products

H3B-6545

G1T48

GDC-9545

SAR439859

AZD9833

Contents

Introduction

Executive Summary

ER+/ HER2 -ve Breast Cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

ER+/ HER2 -ve Breast Cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

ER+/ HER2 -ve Breast Cancer companies' collaborations, Licensing, Acquisition
-Deal Value Trends

ER+/ HER2 -ve Breast Cancer Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Rintodestrant (G1T48): G1 Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

ER+/ HER2 -ve Breast Cancer Key Companies

ER+/ HER2 -ve Breast Cancer Key Products

ER+/ HER2 -ve Breast Cancer- Unmet Needs

ER+/ HER2 -ve Breast Cancer- Market Drivers and Barriers

ER+/ HER2 -ve Breast Cancer- Future Perspectives and Conclusion

ER+/ HER2 -ve Breast Cancer Analyst Views

ER+/ HER2 -ve Breast Cancer Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for ER+/ HER2 -ve Breast Cancer

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for ER+/ HER2 -ve Breast Cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: ER+/ HER2 -ve Breast Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/EE3BCD247134EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EE3BCD247134EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970